Predictors of erythropoietin use in patients with cardiorenal anaemia syndrome

E-ISSN： 2042-7174|23|3|199-204

ISSN： 0961-7671

Source： International Journal Of Pharmacy Practice, Vol.23, Iss.3, 2015-06, pp. : 199-204

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Plasma Adrenomedullin and Subclinical Cardiorenal Syndrome in Patients with Type 2 Diabetes Mellitus

By Pecková M Charvat J Schuck O Zamrazil V Bilek R Hill M Svab P Horackova M

The Journal of International Medical Research, Vol. 40, Iss. 4, 2012-07 ,pp. : 1552-1559

Field House Publishing

Access to resources Recommend Favorite

Role of Asymmetric Dimethylarginine in Cardiorenal Syndrome

Current Pharmaceutical Design, Vol. 20, Iss. 14, 2014-04 ,pp. : 2448-2455

Bentham Science Publishers

Access to resources Recommend Favorite

Epoetin Beta: A Review of its Clinical Use in the Treatment of Anaemia in Patients with Cancer

By Cheer S.M. Wagstaff A.J.

Drugs, Vol. 64, Iss. 3, 2004-01 ,pp. : 323-346

Adis International

Access to resources Recommend Favorite

Recombinant erythropoietin favoured in chemo-related anaemia

Inpharma, Vol. 1, Iss. 1587, 2007-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Recombinant erythropoietin favoured in chemo-related anaemia

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 527, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite